Regeneron Drug Prevented Bone Growth in FOP Study
The monoclonal antibody Pasatru limited new lesions in an 84-week trial for patients with a rare genetic bone disorder.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you trust that new drug trial results reliably indicate the long-term value of pharmaceutical companies?
Regeneron reported 84-week results from the Phase 3 OPTIMA trial, showing that its drug Pasatru successfully prevented new heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva. The trial findings were presented on October 12, 2026, marking a significant outcome for managing this rare genetic condition.
Why it matters
By targeting the Activin A protein, Pasatru addresses the underlying biological trigger for the transformation of soft tissue into bone. This therapy offers a potential pathway to mitigate the debilitating flare-ups associated with this progressive disease.
The OPTIMA trial monitored 63 adults over 84 weeks, finding zero new lesions in treated patients compared to nine new lesions in the placebo group. The 10 mg/kg dosage effectively inhibited Activin A activity to prevent soft tissue calcification.
The players
Regeneron
A biotechnology company focused on developing human monoclonal antibodies for the treatment of inflammatory, rare, and eye diseases.
The details
Pasatru is a human monoclonal antibody—a laboratory-produced molecule designed to act as a substitute antibody to restore, enhance, or mimic the immune system's attack on target cells. It functions by inhibiting the Activin A protein, a signaling molecule that, when overactive, causes soft tissues to harden into bone. This mechanism prevents the body's inflammatory response from triggering permanent ossification in affected areas.
Timeline
Week 56: The trial met its primary endpoint.
Week 84: Data collection for the reported results concluded.
October 12, 2026: Regeneron presented the trial findings.
Later this year: The company plans to initiate the OPTIMA 2 trial for children and adolescents.
The Tech Race
The presentation at the American Society for Bone and Mineral Research marks a critical milestone in the competitive landscape for orphan drug development targeting rare skeletal conditions. Regeneron now seeks to expand this efficacy data into younger populations through its upcoming OPTIMA 2 trial.
This development represents a significant step toward a new treatment option for patients currently living with fibrodysplasia ossificans progressiva. Clinicians and patients can monitor the upcoming OPTIMA 2 trial as the next phase of evidence for expanding the treatment's patient reach.
The takeaway
The clinical results suggest a strong efficacy in preventing heterotopic ossification through protein inhibition. Stakeholders should track the initiation of the OPTIMA 2 trial later this year to see if the safety and efficacy profile holds across pediatric populations.
What happens next
Regeneron is scheduled to initiate the OPTIMA 2 clinical trial for adolescents and children later this year.
Further reading
Learn more about the latest developments in medical innovation in our Biotech section.
Live Poll
Do you trust that new drug trial results reliably indicate the long-term value of pharmaceutical companies?
